Dr. David Almeida Cardoso is a medical scientist by training, having undertaken a research doctorate at University of Sydney and Children’s Medical Research Institute investigating the development of novel drug candidates for epilepsy. Following graduation, he shifted focus toward the business world, holding project management and commercialisation positions with the medical research ecosystem, all while studying an MBA. He is currently the Vice President, Business Development and Strategy at Pending AI (drug discovery platform enabled by artificial intelligence and quantum mechanics), where he is responsible for initiating and scaling US operations, as well as legal, business development, commercial and scientific strategy, and funding acquisition (grants and investment) globally.